Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 573Breast 214Head & Neck 39Tumor-Agnostic 14Endocrine 14Genitourinary 13CNS 13Gynecologic 10Other solid neoplasm 8NET 8Thoracic 7Other neoplasm 3Dermatologic 2Sarcoma 1

Conditions

Stomach Neoplasms 1Gastrointestinal Stromal Tumors 1

Interventions

Cyclophosphamide 93Doxorubicin 92Radiotherapy 87Temozolomide 69Filgrastim 58Ifosfamide 55Bevacizumab 55Etoposide 48Gemcitabine 44Imatinib Mesylate 43Vincristine 40pembrolizumab 35pazopanib 34Peripheral Blood Stem Cell Transplantation 31Methotrexate 31Nivolumab 30Carboplatin 30fludarabine phosphate 29Irinotecan 29Cisplatin 28Paclitaxel 26Melphalan 26Magnetic Resonance Spectroscopy 26Docetaxel 25Busulfan 25Trabectedin 24apatinib 22Specimen Handling 21Sirolimus 21Antilymphocyte Serum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Capecitabine × Sarcoma × Clear all
NCT00780494 2025-01-14

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Stanford University

Phase 2 Completed
35 enrolled 13 charts
GastrointestinalSarcoma

Stomach Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡